LIGAND PHARMACEUTICALS INCORPORATED Finance Lease, Interest Expense
LIGAND PHARMACEUTICALS INCORPORATED (LGNYZ) reported Finance Lease, Interest Expense of $700.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Interest Expense
us-gaap:FinanceLeaseInterestExpense · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED finance lease, interest expense for fiscal 2025 was $700.00K, a 40.00% increase from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED finance lease, interest expense for fiscal 2024 was $500.00K, a 28.57% decline from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED finance lease, interest expense for fiscal 2023 was $700.00K, a 69.57% decline from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED finance lease, interest expense for fiscal 2022 was $2.30M, a 0.00% change from fiscal 2021.
| Period end | Finance Lease, Interest Expense 12 month |
|---|---|
| 2025-12-31 | $700.00K 10-K · filed 2026-02-27 |
| 2024-12-31 | $500.00K 10-K · filed 2026-02-27 |
| 2023-12-31 | $700.00K 10-K · filed 2026-02-27 |
| 2022-12-31 | $2.30M 10-K · filed 2024-02-29 |
| 2021-12-31 | $2.30M 10-K · filed 2023-02-28 |
| 2020-12-31 | $200.00K 10-K · filed 2022-02-28 |